Clinical Guidelines for Structured Radiomics Reporting in Clinical Practice

Abstract

Radiomics, the high-throughput extraction of quantitative imaging features from medical images, has emerged as a transformative tool in precision medicine. However, its clinical translation is hindered by heterogeneity in reporting standards, limiting reproducibility and utility. This review presents a comprehensive overview of clinical guidelines for structured radiomics reporting, emphasizing current evidence, clinical relevance, and practical recommendations for healthcare professionals. The aim is to promote standardization, enhance communication, and improve patient care outcomes by integrating structured radiomics into routine clinical workflows.

Introduction

Radiomics leverages computational algorithms to extract a vast array of quantitative features from radiological images, offering objective data to inform diagnosis, prognosis, and therapeutic decision-making. Despite its promise, clinical implementation faces significant obstacles due to inconsistencies in study design, feature extraction, and reporting. In response, international efforts have focused on developing consensus guidelines and structured reporting frameworks to improve reproducibility, comparability, and clinical impact. This article reviews epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, recent advances, and guideline recommendations for structured radiomics reporting, providing actionable insights for clinicians and researchers.

Epidemiology / Disease Burden

The global adoption of radiomics in clinical research has grown exponentially in the last decade, particularly in oncology, neurology, and cardiology. According to a 2023 analysis of PubMed-indexed articles, over 5,000 publications addressed radiomics, with significant focus on lung, prostate, and brain tumors. The heterogeneity in reporting and lack of standardized protocols have limited the translation of radiomics into routine practice, resulting in variable clinical impact. The burden lies not only in underutilized data but also in the risk of inconsistent patient outcomes due to non-reproducible findings. Standardized guidelines are critical for leveraging radiomics as a reliable adjunct in clinical decision-making.

Pathophysiology

Radiomics is rooted in the concept that medical images contain quantifiable patterns reflecting underlying tissue biology and pathophysiological processes. By extracting and analyzing features such as texture, shape, and intensity, radiomics provides surrogate biomarkers for disease characterization. These features can reveal tumor heterogeneity, hypoxia, angiogenesis, and microenvironmental alterations otherwise invisible to the human eye. Mechanistically, radiomics bridges the gap between radiology and molecular pathology, enabling non-invasive phenotyping and risk stratification. Understanding the biological relevance of radiomic features underpins their integration into structured reporting and clinical workflows.

Risk Factors

The accuracy and clinical utility of radiomics depend on multiple factors, including image acquisition protocols, scanner variability, patient movement, and segmentation techniques. Operator-dependent variability, inconsistent annotation, and lack of harmonization across centers pose significant risks for reproducibility. Additionally, patient-specific factors such as comorbidities, prior interventions, and demographic characteristics can introduce confounding effects. Recognizing and mitigating these risk factors through standardized reporting and quality control measures is essential for reliable radiomics implementation in clinical settings.

Clinical Features

Structured radiomics reporting enhances the assessment of various clinical features across diseases, particularly in oncology. Examples include tumor heterogeneity, necrosis, edema, and vascular invasion as detected in imaging studies of brain, lung, and liver cancers. Radiomics can also capture subtle changes in tissue architecture, correlating with histopathological grades, molecular subtypes, and therapeutic responses. By providing objective, quantifiable descriptors, structured reporting facilitates multidisciplinary communication, supports clinical trial design, and augments personalized treatment planning.

Diagnosis

Accurate diagnosis is central to effective patient care. Radiomics offers potential to improve diagnostic precision by capturing high-dimensional imaging features linked to disease phenotypes. Structured reporting of radiomics ensures transparent documentation of imaging protocols, feature selection, and statistical methods. This clarity enhances reproducibility and comparability across studies, supporting evidence-based diagnostic algorithms. Several guidelines, such as the Image Biomarker Standardization Initiative (IBSI) and the Radiomics Quality Score (RQS), advocate for detailed reporting of image acquisition, preprocessing, feature extraction, and model validation steps.

Treatment & Management

Radiomics has been increasingly integrated into treatment planning and response assessment, particularly in radiation oncology and targeted therapies. Structured reporting allows clinicians to track changes in tumor burden, predict treatment response, and identify early signs of resistance or recurrence. By adhering to standardized guidelines, healthcare teams can ensure that radiomics-derived insights are interpretable, actionable, and reproducible, ultimately improving patient management. Integration with electronic health records and multi-disciplinary tumor boards further enhances the clinical utility of structured radiomics reports.

Recent Advances / Emerging Therapies

Recent advancements in artificial intelligence and machine learning have propelled radiomics into new frontiers, enabling automated feature extraction, deep learning-based phenotyping, and multi-omics integration. Emerging therapies, such as immunotherapy and precision radiotherapy, benefit from radiomics-driven biomarkers that predict response and guide dose adaptation. Efforts to harmonize imaging protocols, develop open-source radiomics platforms, and establish international consortia are accelerating the translation of radiomics from research to routine care. Structured reporting remains foundational to these advances, ensuring that novel radiomics applications are evidence-based and clinically relevant.

Guideline Recommendations

Multiple international societies have issued consensus guidelines to promote standardized radiomics reporting. Key recommendations include: (1) comprehensive documentation of imaging acquisition and reconstruction parameters; (2) transparent reporting of segmentation protocols and inter-observer variability; (3) detailed description of feature extraction methods, including software and parameter settings; (4) rigorous statistical validation, including external validation cohorts and calibration metrics; and (5) clear reporting of clinical endpoints and integration with existing clinical models. The IBSI, RQS, Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD), and CONSORT-AI provide frameworks to guide authors, reviewers, and clinicians in structured radiomics reporting. Adherence to these guidelines is essential for regulatory approval, clinical adoption, and ongoing research.

Conclusion

Structured radiomics reporting is pivotal for the clinical adoption of quantitative imaging biomarkers. Standardized guidelines enhance reproducibility, facilitate multicenter collaborations, and improve patient outcomes by integrating objective imaging data into clinical workflows. Ongoing efforts to harmonize reporting frameworks, advance computational methods, and foster clinician education will shape the future of radiomics in precision medicine. By embracing structured reporting, the medical community can harness the full potential of radiomics to deliver personalized, evidence-based care.